ES2000384A6 - Synergistic antiviral and antitumour compsns. - contg. cpd. with antiviral and antitumour activity, pref. xanthate, and cpd. contg. both hydrophilic and lipophilic gps., e.g. decanoic acid - Google Patents

Synergistic antiviral and antitumour compsns. - contg. cpd. with antiviral and antitumour activity, pref. xanthate, and cpd. contg. both hydrophilic and lipophilic gps., e.g. decanoic acid

Info

Publication number
ES2000384A6
ES2000384A6 ES8600811A ES8600811A ES2000384A6 ES 2000384 A6 ES2000384 A6 ES 2000384A6 ES 8600811 A ES8600811 A ES 8600811A ES 8600811 A ES8600811 A ES 8600811A ES 2000384 A6 ES2000384 A6 ES 2000384A6
Authority
ES
Spain
Prior art keywords
antiviral
antitumour
cpd
alkyl
contg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES8600811A
Other languages
Spanish (es)
Inventor
Gerhard Sauer
Eberhard Amtmann
Hummel Klaus W
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CT-HOLDING SA
Original Assignee
Merz and Co GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz and Co GmbH and Co KG filed Critical Merz and Co GmbH and Co KG
Publication of ES2000384A6 publication Critical patent/ES2000384A6/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

(A) New antiviral and antitumour compsns. contain (1) an active substance with antiviral and antitumour activity and (2) an adjuvant cpd. which contains in its molecule at least one lipophilic- and at least one hydrophilic-gp. (B) New pharmaceutical prepns. intended to administration before, simultaneously with or after pharmaceutical prepns. with antiviral and antitumour activity, which increase the activity of the antiviral/antitumour prepns. contain as the synergistically acting active substance at least one cpd. contg. in its molecule at least one lipophilic- and at least one hydrophilic-gp. Pref. antitumour/antiviral active substances xanthate derivs. of formula (I) (R1 is norbornyl, tricyclodecyl, benzyl, 3-20C (cyclo)alkyl, furyl, pyridyl, quinuclidinyl, 3-20C alkyl substd. by at least one OH or 1-4C alkoxy or halogenation, or 3-20C cycloalkyl substd. by at least one OH, 1-4C alkoxy or 1-4C alkyl or halogen atom R2 is one equiv. of a mono- or polyvalent metal ion, 2,3-dihydroxypropyl, omega-hydroxy-(1-4C alkoxy)-methyl, or 1-6C alkyl opt. substd. by at least one OH, 1-4C alkoxy, amino, di(1-4C alkyl)amino or tri-(1-4C alkyl)amino or halogen atom). The adjuvant cpd. (component 2) pref. carries a 6-18C aliphatic gp. as the lipophilic gp. and 1-2 carboxy, sulphate, sulphonate or phospate gps. as hydrophilic gps. and may be in the form of a pharmaceutically acceptable salt.
ES8600811A 1985-08-02 1986-08-01 Synergistic antiviral and antitumour compsns. - contg. cpd. with antiviral and antitumour activity, pref. xanthate, and cpd. contg. both hydrophilic and lipophilic gps., e.g. decanoic acid Expired - Fee Related ES2000384A6 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3527871 1985-08-02

Publications (1)

Publication Number Publication Date
ES2000384A6 true ES2000384A6 (en) 1991-03-16

Family

ID=6277597

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8600811A Expired - Fee Related ES2000384A6 (en) 1985-08-02 1986-08-01 Synergistic antiviral and antitumour compsns. - contg. cpd. with antiviral and antitumour activity, pref. xanthate, and cpd. contg. both hydrophilic and lipophilic gps., e.g. decanoic acid

Country Status (7)

Country Link
KR (1) KR860008777A (en)
AT (1) AT388499B (en)
CS (1) CS275793B6 (en)
DD (1) DD286971A5 (en)
ES (1) ES2000384A6 (en)
HU (1) HU197212B (en)
PT (1) PT83127B (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1140M (en) * 1961-05-16 1962-02-19 Johnson & Johnson Chemotherapeutic composition has increased efficacy.
US4164573A (en) * 1975-06-13 1979-08-14 Galinsky Alvin M Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
IT1202370B (en) * 1976-07-12 1989-02-09 Hoffmann La Roche INJECTABLE SOLUTIONS IN WHICH THE EMOLITHIC LIFE OF NATURAL MICELLES TRAINING AGENTS IS AVOIDED BY THE ADDITION OF LIPOIDS AND RELATED PRODUCTS
JPS5940137B2 (en) * 1976-10-14 1984-09-28 武田薬品工業株式会社 Pharmaceutical composition for oral administration
JPS54122719A (en) * 1978-03-16 1979-09-22 Sankyo Co Ltd Carcinostatic agent for oral administration
JPS56100711A (en) * 1980-01-16 1981-08-12 Teijin Ltd Pharmaceutical for remedy of uterine cancer
CA1174978A (en) * 1980-11-26 1984-09-25 Arthur Scherm Xanthates
DK170068B1 (en) * 1980-11-26 1995-05-15 Ct Holding Sa Analogous process for the preparation of xanthates
JPS58124714A (en) * 1982-01-20 1983-07-25 Yamanouchi Pharmaceut Co Ltd Oily composition of antitumor substance
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
DE3218121A1 (en) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment

Also Published As

Publication number Publication date
CS8605798A2 (en) 1990-10-12
CS275793B6 (en) 1992-03-18
AT388499B (en) 1989-06-26
KR860008777A (en) 1986-12-18
DD286971A5 (en) 1991-02-14
ATA208786A (en) 1988-12-15
PT83127A (en) 1986-09-01
HU197212B (en) 1989-03-28
HUT42949A (en) 1987-09-28
PT83127B (en) 1989-03-30

Similar Documents

Publication Publication Date Title
US4153689A (en) Stable insulin preparation for nasal administration
ES8301632A1 (en) An orally administered drug form comprising a polar bioactive agent and an adjuvant.
GB9107513D0 (en) Pyrazolopyridine compound and processes for preparation thereof
NO941276D0 (en) Lipophilic, oligosaccharide antibiotic salt preparations
EP0282405A3 (en) Low toxicity drug-lipid systems
CA2042972A1 (en) Treatment of ocular hypertension with a synergistic combination for ocular administration
ES2000384A6 (en) Synergistic antiviral and antitumour compsns. - contg. cpd. with antiviral and antitumour activity, pref. xanthate, and cpd. contg. both hydrophilic and lipophilic gps., e.g. decanoic acid
GB2204867B (en) Antifoliate pyrimidine compounds
EP0209843A3 (en) Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use
IL97648A0 (en) Stabilized 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide pharmaceutical compositions and methods for the preparation thereof
KR950702561A (en) QUINOLINE AND NAPHTHYRIDINE PRODRUGS
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
SI9300150B (en) Crystalline forms of endo-2,3-dihydro-N- (8-methyl-8-azabicyclo [3.2.1 (oct-3-yl) -2-oxo-1 H- benzimidazole- 1 -carboxamide hydrochloride monohydrate and endo-3 -ethyl-2,3-dihydro-N- (8-methyl-8-azabicyclo [3.2.1] oct-3-yl) -2-oxo-1H-benzimidazole-1-carboxamide hydrochloride monohydrate
DK15088D0 (en) ANTIBACTERIAL LYOPHILIZED PREPARATION
HUT56549A (en) Process for producing new imidazole derivatives and pharmaceutical compositions comprising such imidazole derivatives as active ingredient
KR100190869B1 (en) Veterinary treatment
ES2169117T3 (en) USE OF DERIVATIVES OF 2-AMINOPURIN IN THE TREATMENT AND PROFILAXIS OF INFECTION BY VIRUS 7 OF THE HUMAN HERPES.
MY100752A (en) Pharmaceutical composition for combating malaria.
KR940002268A (en) 21-chloro-pregnane derivative
GB1463260A (en) Pharmacologically active acetic acid derivative
EP0354042A3 (en) Aminobenzoic-acid derivatives to reduce side effects induced by an administration of immuno-suppressant
ATE30592T1 (en) PENICILLIN DERIVATIVES.
JPS57139015A (en) Remedy for infectious disease for oral administration
EP0456988A3 (en) Use of naproxen as mydriatic agent
ITRM920173A1 (en) IBUPROFEN-BASED COMPOSITION FOR ORAL USE.

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: CT-HOLDING SA

FD1A Patent lapsed

Effective date: 20001204